The total return over the past 12 months is +0.84% vs. +16.94% for the S&P 500. So far it's up -3.21% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +0.84% | (4.83%) | (12.27%) | (3.60%) | +6.85% | N/A |
| Total Return CAGR | +0.84% | (4.83%) | (12.27%) | (3.60%) | +6.85% | N/A |
| Revenue CAGR | +5.71% | +3.69% | +8.20% | +10.84% | +30.21% | N/A |
| Net Income CAGR | N/A | N/A | (39.06%) | N/A | N/A | N/A |
| EPS CAGR | N/A | (22.96%) | (45.77%) | +12.33% | N/A | N/A |
| Free Cash Flow CAGR | +53.34% | +12.32% | +16.72% | N/A | N/A | N/A |
| Operating Cash Flow CAGR | +39.50% | +8.40% | +7.84% | +22.70% | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Pacira BioSciences, Inc. (PCRX)
| Year | Start price | End price | PCRX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $25.88 | $25.05 | (3.21%) | +14.51% | (17.72%) |
| 2025 | $18.84 | $25.88 | +37.37% | +17.72% | +19.65% |
| 2024 | $33.74 | $18.84 | (44.16%) | +24.89% | (69.05%) |
| 2023 | $38.61 | $33.74 | (12.61%) | +26.19% | (38.80%) |
| 2022 | $60.17 | $38.61 | (35.83%) | (18.17%) | (17.66%) |
| 2021 | $59.84 | $60.17 | +0.55% | +28.74% | (28.19%) |
| 2020 | $45.30 | $59.84 | +32.10% | +18.37% | +13.73% |
| 2019 | $43.02 | $45.30 | +5.30% | +31.22% | (25.92%) |
| 2018 | $45.65 | $43.02 | (5.76%) | (4.56%) | (1.20%) |
| 2017 | $32.30 | $45.65 | +41.33% | +21.70% | +19.63% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
